Showing 1781-1790 of 2123 results for "".
- Rimegepant Dual Treatment Efficacy and Safety Maintained Over a Year of Treatmenthttps://practicalneurology.com/news/rimegepant-dual-treatment-efficacy-and-safety-maintained-over-a-year-of-treatment/2469936/In an open-label extension study (NCT03732638), adults (n-603) treatment with 75 mg of rimegepant (Nurtec; Biohaven, New Haven, CT) every other day, with the option of additional doses as acute treatment on the other days, had reduced
- Aducanumab Treatment for 2 Years or More Decreases Amyloid Beta and Phosphorylated Tau 181 Correlating With Reduced Cognitive Declinehttps://practicalneurology.com/news/aducanumab-treatment-for-2-years-or-more-decreases-amyloid-beta-and-phosphorylated-tau-181-correlating-with-reduced-cognitive-decline/2469853/New data show continued reductions in amyloid β (Aβ) plaques and plasma levels of phosphorylated tau 181 (ptau-181) after 128 weeks of treatment with aducanumab (Aduhelm; Biogen, Cambridge, MA). Participants with greater decreases in Aβ were more likely to have decreased in p-tau18
- Global Ischemic Stroke Mortality Rate Lowered Over Last 30 yearshttps://practicalneurology.com/news/global-ischemic-stroke-mortality-rate-lowered-over-last-30-years/2469782/As published in Neurology, the mortality rates for stroke decreased slightly from 1990 to 2019 worldwide. However, the number of individuals who died is still high, specifically in high- and middl
- Blood Test May Accurately Predict Progression to Alzheimer Disease 6 Years Before Diagnosishttps://practicalneurology.com/news/blood-test-may-accurately-predict-progression-to-alzheimer-disease-6-years-before-diagnosis/2469675/In a retrospective longitudinal study, available as a preprint prior to peer review, a prognostic blood biomarker test (AlzoSure Predict; Diadem, Milan, Italy) identified people who progressed from normal cognition or mild cognitive impairment (MCI) to Alzheimer disease (AD). The study used a con
- Children Treated With Risdiplam Continue Meeting Motor Milestones After 1 Yearhttps://practicalneurology.com/news/children-treated-with-risdiplam-continue-meeting-motor-milestones-after-1-year/2469652/Results from Part 2 of a pivotal clinical study show that infants with symptomatic Type 1 spinal muscular atrophy (SMA) treated with risdiplam (Evrysdi; PTC Therapeutics, South Plainfield, NJ) showed significant improvements in survival, motor milestones, and motor function compared with the natu
- Viltolarsen Treatment of Muscular Dystrophy Improves Mobility Over More Than 2 Yearshttps://practicalneurology.com/news/viltolarsen-treatment-of-muscular-dystrophy-improves-mobility-over-more-than-a-2-years/2469630/Interim analyses of an open-label extension trial (NCT04337112) have shown mobility improvement in individuals with Duchenne muscular dystrophy (DMD) after 109 weeks of treatment with vi
- Vote for Your Favorite Photo at DravetPhotoDiary.com to Support the Epilepsy Foundation and the Dravet Syndrome Foundationhttps://practicalneurology.com/news/vote-for-your-favorite-photo-at-dravetphotodiarycom-to-support-the-epilepsy-foundation-and-the-dravet-syndrome-foundation/2469626/To celebrate the increased functionality that can come with effective treatments for Dravet syndrome, families and individuals living with the condition have been sharing photos of their family life on DravetPhotoDiary.com. Fo
- FDA Allows Study of Bilateral Ultrasound Treatment of Essential Tremorhttps://practicalneurology.com/news/fda-allows-study-of-bilateral-ultrasound-treatment-of-essential-tremor/2469492/The Food and Drug Administration (FDA) has given Investigational Device Exemption (IDE) approval for a pivotal study (NCT04112381) of a device (Exablate Neuro Focus
- Decreased 10-Year Disability Progression in Multiple Sclerosis Seen With Autologous Hematopoietic Stem Cell Treatmenthttps://practicalneurology.com/news/decreased-10-year-disability-progression-in-multiple-sclerosis-seen-with-autologous-hematopoietic-stem-cell-treatment/2469482/A new study published in Neurology suggests autologous hematopoietic stem cell transplant (aHSCT) therapy for multiple sclerosis may have efficacy for preventing disability progression of multiple sclerosi
- Erenumab Reductions in Monthly Migraine Days Sustained for up to 2 Years In Episodic Migrainehttps://practicalneurology.com/news/erenumab-reductions-in-monthly-migraine-days-sustained-for-up-to-2-years-in-episodic-migraine/2469395/In the open-label extension period of a phase 2 study (NCT01952574), treatment with erenumab (Aimovig; Amgen, Thousand Oak, CA) resulted in sustained reductions in monthly migraine days (MMD) and use of acute migraine-specific medications (AMSM). Additionally, the safety profile was consistent wi